Both Dogmatil and Amipride are used to treat a range of mental disorders, particularly schizophrenia and depression. Both belong to the atypical antipsychotic class, but their active ingredients differ, leading to differences in their mechanism of action and potential side effects.

Dogmatil Tablets Ingredients

Dogmatil tablets contain the active ingredient sulpiride. Sulpiride is an antipsychotic that selectively affects dopamine receptors in the brain. At low doses, it can have antidepressant and stimulant effects, while at higher doses, it is primarily used to treat psychosis.

Amipride Tablets Ingredients

Amipride tablets contain the active ingredient amisulpride. Amisulpride is also an atypical antipsychotic that selectively acts on dopamine receptors, particularly D2 and D3 receptors. It is thought to have different dose-dependent effects, with stimulating and antidepressant effects at low doses and antipsychotic effects at higher doses.

Information about Dogmatil tablets

Drug class: Antipsychotics

Drug classification: Benzamides

Pharmaceutical form: Tablets

Pharmaceutical family: Central nervous system drugs

Active ingredient: Sulpiride

Information about Amipride tablets

Drug class: Antipsychotics

Drug class: Benzamides

Pharmaceutical form: Tablets

Pharmaceutical family: Central nervous system drugs

Active ingredient: Amisulpride

Author Name: Dr. Rawan Mossad Elsaed

Scientific Degree: Pharmacist

Country: Egypt

Dr. Rawan Mosaad El-Saeed is a clinical pharmacist and medical content reviewer holding a Bachelor of Pharmacy degree from Horus University in Egypt. She has hands-on community pharmacy experience in providing medication therapy counseling, monitoring drug-drug interactions, and ensuring patient adherence to safe usage protocols. She specializes in authoring and fact-checking pharmaceutical guides and simplifying clinical pharmacology based on the latest evidence-based guidelines and internationally accredited references, dedicated to delivering accurate, reliable, and safe healthcare information for readers.

Published Date: 20 April 2025